Actively Recruiting

Phase Not Applicable
All Genders
NCT04631770

Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC

Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2023-09-28

1362

Participants Needed

1

Research Sites

365 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Lung cancer is the leading cause of cancer related death worldwide. Lobectomy or sub-lobectomy with mediastinal lymph node dissection is the standard surgery. About 50% lung nodules are pure ground-glass or part-solid nodules. Non-solid nodules rarely develop mediastinal lymph node metastasis. The present study is a prospective, multicenter and randomized clinical trial, comparing the overall survival and disease-free survival of whether performing mediastinal lymph node dissection in non-small cell lung cancer with ground-glass nodule CT features.

CONDITIONS

Official Title

Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Thin-slice HRCT shows single ground-glass nodule with consolidation-to-tumor ratio of 0.5 or less and no lymph node metastasis
  • Clinical stage IA non-small cell lung cancer diagnosed before or during surgery
  • No history of other malignancies within past 5 years or previous lung surgery
  • No anti-cancer treatment before surgery
Not Eligible

You will not qualify if you...

  • Presence of simultaneous or metachronous double cancers within past 5 years
  • Active bacterial or fungal infection
  • Interstitial pneumonitis, pulmonary fibrosis, or severe pulmonary emphysema
  • Use of systemic steroid medication
  • Uncontrolled diabetes mellitus
  • Uncontrolled hypertension or severe heart disease or heart failure history

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Ethics review board of Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, China, 300060

Actively Recruiting

Loading map...

Research Team

Z

Zhenfa Zhang, MD

CONTACT

C

Chenguang Li, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC | DecenTrialz